1020409-67-9

Upstream product

• 74801-29-9 phenyl-2,3,4,6-tetra-O-benzyl-1-thio-β-D-galactopyranoside 
• 78153-79-4 2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl fluoride 
• 100-39-0 benzyl bromide 
• 25878-60-8 D-galactose pentaacetate 
• 1020409-56-6 tert-butyl (2S,3R)-3-(tert-butyldiphenylsilyloxy)-1-hydroxypent-4-en-2-ylcarbamate 
• 1020409-65-7 (2S,3R)-2-(tert-butyloxycarbonylamino)-3-O-(tert-butyldiphenylsilyl)-1-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl)pent-4-ene 

Downstream Products

• 1020409-85-1 (2S,3R,6R,7S)-2,7-(di-tert-butyloxycarbonylamino)-3,6-dihydroxy-1,8-di(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl)oct-4-ene 
• 1020409-91-9 (4S,5S)-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosylmethyl)-5-vinyl-1,3-oxazolidin-(3H)-2-one 
• 1020409-90-8 (3R,4S)-4-(tert-butyloxycarbonylamino)-3-fluoro-5-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl)pent-1-ene 

Relevant academic research and scientific papers

Focus on the controversial activation of human iNKT cells by 4-deoxy analogue of KRN7000

4-Deoxy-α-GalCer analogues are considered weaker agonists than KRN7000 for the stimulation of human iNKT cells, but this remains strongly debated. In this work, we described a strategy toward 4-deoxy-α-GalCers with, as a key step, a metathesis reaction al

ALPHA-GALACTOSYLCERAMIDE ANALOGS, THEIR METHODS OF MANUFACTURE, INTERMEDIATE COMPOUNDS USEFUL IN THESE METHODS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

The invention relates to α-galactoceramide analogs, their methods of manufacture, intermediate compounds useful in these methods. It also relates to pharmaceutical compositions containing the α-galactoceramide analogs. The methods of manufacture of the invention involve the use of unsaturated intermediate compounds which enable to synthesize α-galactoceramide analogs by a mere metathesis reaction. The α-galactoceramide analogs of the invention are useful as active ingredients of pharmaceutical compositions, particularly in pharmaceutical compositions having anti-cancerous properties.